Specifically, our XACIATO product launch and first commercial sale by Organon. As John mentioned, we are working together to achieve a 2023 launch as soon as feasible. Patient enrollment in the Phase 3 clinical study of Ovaprene, our investigational potential first in category, hormone-free monthly intravaginal contraceptive, whose US commercial rights are under the license agreement with Bayer. And as we just discussed, we expect that single pivotal study to support Ovaprene’s pre-market, approval application and enrollment is targeted to commence this fourth quarter of this year. We’re also looking forward to our end of Phase 2 meeting with the FDA and finalization of a Phase 3 protocol for the next Sildenafil Cream study. In addition, we look forward to announcing data later this year from our Phase 1 study evaluating a vaginal gel formulation of Aceclofenac being developed as a treatment for menstrual pain and cramps, as well as ongoing activities related to IND and Phase 3 and Phase 2, preparations for our two menopause programs, hormone therapy for the vasomotor symptoms of menopause and hormone free vulvovaginal atrophy treatment respectively.
So with that, I thank you again for your time today and for your support. Thank you.
Operator: This concludes today’s conference call. You may now disconnect.
